Business Wire

Hologic Showcases Advances across the Continuum of Breast Health at ECR 2022

Share

Hologic, Inc. (Nasdaq: HOLX) will showcase their comprehensive portfolio of breast and skeletal health solutions at the annual European Congress of Radiology (ECR) in Vienna, Austria from July 13-17.

The pioneer behind 3D Mammography™ technology, Hologic will provide attendees with an interactive experience that underscores a commitment to innovation through advancements in breast screening, surgery, biopsy and ultrasound solutions. As visitors explore the clinically proven, integrated solutions across Hologic’s Breast Health Continuum of Care, they can understand how these technologies support the early detection and diagnostic needs of patients.

“We’re thrilled to return to ECR to showcase how Hologic’s product portfolio can support the needs of radiologists and patients throughout the continuum of breast health,” said Tanja Brycker, Vice President, Strategic Development, Breast and Skeletal Health and Gynecological Surgical Solutions at Hologic. “Our portfolio is designed to tackle today’s biggest challenges to early detection‚ such as pandemic delays and radiology backlogs, in order to help remove these barriers to diagnosis and treatment.”

Hologic’s ECR presence will also include the Scientific Innovation Hub, where a wide variety of scientific talks led by experts in the field will be hosted throughout the event. Medical education sessions will focus on current topics, ranging from personalization in breast cancer detection, contrast-enhanced mammography in clinical practice, trends and practices in biopsy and lesion localization, and ultrasound in clinical practice for breast and liver. A full list of sessions will be available at the Hub.

Additionally, the booth will feature findings from the Hologic Global Women’s Health Index, developed in collaboration with the Gallup World Poll. This multiyear, comprehensive global survey provides an understanding of women’s perspectives and experiences on key health topics. Throughout ECR, Hologic will share highlights from the inaugural survey released in September 2021, so attendees can learn about the state of women's health in their region.

For more information, or to register for a scientific session, stop by Hologic’s booth in Foyer O on the first floor of the ACV Main Congress building.

About Hologic, Inc.

Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.

Hologic and 3D Mammography are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.

Forward-Looking Statements

This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.

SOURCE: Hologic, Inc.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jane Mazur
+1 508.263.8764 (direct)
jane.mazur@hologic.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mary Kay Inc. Continues Its Support of Women’s Empowerment at the International Women’s Forum Cornerstone Conference in Chile12.8.2022 18:33:00 CEST | Press release

Mary Kay Inc. continues its support of women’s entrepreneurship, empowerment and thought leadership as a sponsor of the 2022 International Women’s Forum (IWF) Cornerstone Conference. Taking place on 17-18 May in Santiago, the Conference convened global decision makers who explored the most pressing challenges to progress on gender equality for the Latin American region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220812005257/en/ IWF Latinobarómetro MKI Latin American Women Democracy & Society from a Gender Perspective Research (Graphic: Mary Kay Inc.) For the first time ever, IWF commissioned groundbreaking research as part of its annual conference programming with funding by Mary Kay. Conducted by the Latinobarómetro founded by Marta Lagos, this research, titled “Latin American Women: Democracy & Society from a Gender Perspective,” is the first-ever analysis of a quarter of a century (1995-2020) of public opinion and at

Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology12.8.2022 17:35:00 CEST | Press release

Regulatory News: Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: IPSEY) today announced the closing of the definitive merger agreement under which Ipsen has acquired Epizyme, Inc. (Epizyme). Pursuant to the transaction, Ipsen acquires all outstanding shares of Epizyme for $1.45 per share plus a contingent value right (CVR) of $1.00 per share. Epizyme now operates as ‘an Ipsen company’ at deal close. As part of the transaction, Ipsen acquires Epizyme’s lead medicine, Tazverik® (tazemetostat), a first-in-class, chemotherapy-free EZH2a inhibitor, which was granted Accelerated Approval by the U.S. Food and Drug Administration (FDA) in 2020. It is currently indicated for adults with relapsed or refractory follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least two prior systemic therapies, and for adult patients with relapsed or refractory follicular lymphom

Budweiser Celebrates 100 Days to The FIFA World Cup™ by Partnering with Messi, Neymar Jr. and Sterling to Drop Hundreds of Prizes For Fans Around the World12.8.2022 13:00:00 CEST | Press release

Tomorrow, Budweiser, an Anheuser-Busch InBev (AB InBev) global brand will “drop” prizes in select destinations in the lead up to the biggest global sporting event. As the Official Beer of the FIFA World Cup, Budweiser is giving fans the once-in-a-lifetime chance to experience the FIFA World Cup in person by dropping hundreds of red prize boxes in major cities that include signed memorabilia, a year’s supply of Budweiser, and the grand prize of a trip to the tournament. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220812005051/en/ Budweiser's QR code (Graphic: Business Wire) Beginning August 13, coordinates leading to prize boxes will be revealed to fans who scanned exclusive Budweiser QR codes. These exclusive QR codes were shared on Budweiser and athlete partner social accounts earlier this week, spurring curiosity and excitement from eager fans. QR codes appeared in locations commemorating Messi, Neymar Jr. and Sterling;

Q4 Inc. Announces Second Quarter 2022 Results12.8.2022 13:00:00 CEST | Press release

Q4 Inc. (TSX:QFOR) (“Q4” or the “Company”), a leading capital markets communications platform, today announced its financial results for the three and six months period ended June 30, 2022. All amounts are expressed in US dollars unless otherwise stated. “The second quarter results show our continued progress against our overall strategy and vision,” said Darrell Heaps, CEO of Q4. “We achieved double digit recurring revenue growth, driving product adoption with higher ARPA expansion growth, as our customers continued to renew subscriptions at record levels and increase their spend with Q4. Given the challenging macro environment, and with our peak investment period behind us, we are accelerating our path to profitability. With a focus on expanding our operating leverage, initiatives are underway to improve sales efficiency and utilize low cost geographies to drive down operating expenses. Combined with our gross margin expansion, these will bring forward our commitment to be cash and E

Zayed Sustainability Prize 2023 Demonstrates Global Reach and Impact with over 4,500 Submissions11.8.2022 16:48:00 CEST | Press release

Following a successful 4-month submissions phase, the Zayed Sustainability Prize, the UAE's pioneering global award for recognising excellence in sustainability, has officially closed entries for its 2023 awards cycle. Over 4,500 applications were received across the five Prize categories of Health, Food, Energy, Water and Global High Schools, from a record 152 countries, demonstrating the Prize’s growing global reach and impact. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220811005418/en/ The Zayed Sustainability Prize 2023 receives more than 4,500 submissions globally (Graphic: AETOSWire) The Zayed Sustainability Prize winners will be announced at the 2023 Zayed Sustainability Prize Awards Ceremony that will be held on January 16, 2023 as part of Abu Dhabi Sustainability Week. The Prize witnessed a 13% increase in submissions compared to last year from small and medium-sized enterprises (SMEs), nonprofit organisations a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom